Gene Expression Analysis of Tumor Spheroids Reveals a Role for Suppressed DNA Mismatch Repair in Multicellular Resistance to Alkylating Agents

REFERENCES

• Borst, P. 1991. Genetic mechanisms of drug resistance. Rev. Oncol. 4:87–105.
   Google Scholar
• Bradley, G., Juranka P. F., and Ling V.. 1988. Mechanisms of multidrug resistance. Biochem. Biophys. Acta 948:87–128.
   PubMed Web of Science ®Google Scholar
• Branch, P., Aquilina G., Bignami M., and Karran P.. 1993. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362:652–654.
   PubMed Web of Science ®Google Scholar
• Desoize, B., and Jardillier J.. 2000. Multicellular resistance: a paradigm for clinical resistance? Crit. Rev. Oncol. Hematol. 36:193–207.
   PubMed Web of Science ®Google Scholar
• Drummond, J. T., Anthoney A., Brown R., and Modrich P.. 1996. Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem. 271:19645–19648.
   PubMed Web of Science ®Google Scholar
• Fan, D. 1994. Reversal of multidrug resistance, p. 93–125. In Kellen J. A. (ed.), Reversal of multidrug resistance in cancer. CRC Press, Boca Raton, Fla.
   Google Scholar
• Francia, G., Mitchell S. D., Moss S. E., Hanby A. M., Marshall J. F., and Hart I. R.. 1996. Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression. Cancer Res. 56:3855–3858.
   PubMedGoogle Scholar
• Frankel, A., Man S., Elliott P., Adams J., and Kerbel R. S.. 2000. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 6:3719–3728.
   PubMed Web of Science ®Google Scholar
• Fritzell, J. A., Narayanan L., Baker S. M., Bronner C. E., Andrew S. E., Prolla T. A., Bradley A., Jirik F. R., Liskay R. M., and Glazer P. M.. 1997. Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res. 57:5143–5147.
   PubMedGoogle Scholar
• Graham, C. H., Kobayashi H., Stankiewicz K. S., Man S., Kapitain S. J., and Kerbel R. S.. 1994. Rapid acquisition of multicellular drug resistance after a single transient exposure of mammary tumor cells to alkylating agents. J. Natl. Cancer Inst. 86:975–982.
   PubMed Web of Science ®Google Scholar
• Green, S. K., Francia G., Isidoro C., and Kerbel R. S.. 2004. Anti-adhesive antibodies targeting e-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol. Cancer Ther. 3:149–159.
   PubMedGoogle Scholar
• Green, S. K., Frankel A., and Kerbel R. S.. 1999. Adhesion-dependent multicellular drug resistance. Anti-Cancer Drug Design 14:153–168.
   PubMedGoogle Scholar
• Houghton, P. J., and Kaye S. B.. 1994. Multidrug resistance is not an important factor in therapeutic outcome in human malignancies. J. NIH Res. 6:55.
   Google Scholar
• Jain, R. K. 1989. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81:570–576.
   PubMed Web of Science ®Google Scholar
• Jeltsch, M., Kaipainen a., Joukov V., Meng X., Lakso M., Rauvala H., Swartz M., Fukumura D., Jain R. K., and Alitalo K.. 1997. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423–1425.
   PubMed Web of Science ®Google Scholar
• Kartner, N., Riordan J. R., and Ling V.. 1983. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285–1288.
   PubMed Web of Science ®Google Scholar
• Kerbel, R. S., Rak J., Kobayashi H., Man M. S., St. Croix B., and Graham C. H.. 1994. Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. Cold Spring Harbor Symp. Quant. Biol. 59:661–672.
   Google Scholar
• Kobayashi, H., Man S., Kapitain S. J., Teicher B. A., and Kerbel R. S.. 1993. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc. Natl. Acad. Sci. USA 90:3294–3298.
   PubMed Web of Science ®Google Scholar
• Lal, A., Peters H., St Croix B., Harpoon Z. A., Dewhirst M. W., Strausberg R. L., Kaanders J. H., van der Kogel A. J., and Riggins G. J.. 2001. Transcriptional response to hypoxia in human tumors. J. Natl. Cancer Inst. 93:1337–1343.
   PubMed Web of Science ®Google Scholar
• Liang, P., and Pardee A. B.. 1992. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257:967–971.
   PubMed Web of Science ®Google Scholar
• Mansbridge, J. N., Ausserer W. A., Knapp M. A., and Sutherland R. M.. 1994. Adaptation of EGF receptor signal transduction to three-dimensional culture conditions: changes in surface receptor expression and protein tyrosine phosphorylation. J. Cell Physiol. 161:374–382.
   PubMedGoogle Scholar
• Martin, S. J., and Green D. R.. 1994. Apoptosis as a goal of cancer therapy. Curr. Opin. Cell Biol. 6:616–621.
   Google Scholar
• Mihaylova, V. T., Bindra R. S., Yuan J., Campisi D., Narayanan L., Jensen R., Giordano F., Johnson R. S., Rockwell S., and Glazer P. M.. 2003. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol. Cell. Biol. 23:3265–3273.
   PubMed Web of Science ®Google Scholar
• Morin, P. J., Downs J. A., Snodgrass A. M., and Gilmore T. D.. 1995. Genetic analysis of growth inhibition by GAL4-L κ B-α in Saccharomyces cerevisiae. Cell Growth Differ. 6:789–798.
   PubMedGoogle Scholar
• Murphy, B. J., Laderoute K. R., Vreman H. J., Grant T. D., Gill N. S., Stevenson D. K., and Sutherland R. M.. 1993. Enhancement of heme oxygenase expression and activity in A431 squamous carcinoma multicellular tumor spheroids. Cancer Res. 53:2700–2703.
   PubMed Web of Science ®Google Scholar
• Nicolaides, N. C., Kinzler K. W., and Vogelstein B.. 1995. Analysis of the 5′ region of PMS2 reveals heterogeneous transcripts and a novel overlapping gene. Genomics 29:329–334.
   PubMedGoogle Scholar
• Nicolaides, N. C., Littman S. J., Modrich P., Kinzler K. W., and Vogelstein B.. 1998. A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. Mol. Cell. Biol. 18:1635–1641.
   PubMed Web of Science ®Google Scholar
• Nicolaides, N. C., Papadopoulos N., Liu B., Wei Y. F., Carter K. C., Ruben S. M., Rosen C. A., Haseltine W. A., Fleischmann R. D., and Fraser C. M.. 1994. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371:75–80.
   PubMed Web of Science ®Google Scholar
• Olive, P. L., and Durand R. E.. 1994. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev. 13:121–138.
   PubMed Web of Science ®Google Scholar
• Phillips, R. M., de la Cruz A., Traver R. D., and Gibson N. W.. 1994. Increased activity and expression of NAD(P)H: quinone acceptor oxidoreductase in confluent cell cultures and within multicellular spheroids. Cancer Res. 54:3766–3771.
   PubMedGoogle Scholar
• Prolla, T. A., Baker S. M., Harris A. C., Tsao J. L., Yao X., Bronner C. E., Zheng B., Gordon M., Reneker J., Arnheim N., Shibata D., Bradley A., and Liskay R. M.. 1998. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat. Genet. 18:276–279.
   PubMed Web of Science ®Google Scholar
• Sakata, K., Kwok T. T., Gordon G. R., Waleh N. S., and Sutherland R. M.. 1994. Resistance to verapamil sensitization of multidrug resistant cells grown as multicellular spheroids. Int. J. Cancer 59:282–286.
   PubMedGoogle Scholar
• St. Croix, B., Florenes V. A., Rak J. W., Flanagan M., Bhattacharya N., Slingerland J. M., and Kerbel R. S.. 1996. Impact of the cyclin dependent kinase inhibitor p27Kip1 on adhesion-dependent resistance of tumor cells to anticancer agents. Nat. Med. 2:1204–1210.
   PubMed Web of Science ®Google Scholar
• St. Croix, B., and Kerbel R. S.. 1997. Cell adhesion and drug resistance in cancer. Curr. Opin. Cell Biol. 9:549–556.
   Google Scholar
• St. Croix, B., Rak J. W., Kapitain S., Sheehan C., Graham C. H., and Kerbel R. S.. 1996. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J. Natl. Cancer Inst. 88:1285–1296.
   PubMed Web of Science ®Google Scholar
• St. Croix, B., Sheehan C., Rak J. W., Florenes V. A., Slingerland J. M., and Kerbel R. S.. 1998. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27KIP1. J. Cell Biol. 142:557–571.
   PubMedGoogle Scholar
• Sutherland, R. M. 1988. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240:177–184.
   PubMed Web of Science ®Google Scholar
• Teicher, B. A., Herman T. S., Holden S. A., Wang Y., Pfeffer M. R., Crawford J. W., and Frei III E.. 1990. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247:1457–1461.
   PubMed Web of Science ®Google Scholar
• Tunggal, J. K., Melo T., Ballinger J. R., and Tannock I. F.. 2000. The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers. Int. J. Cancer 86:101–107.
   PubMed Web of Science ®Google Scholar
• Waleh, N. S., Gallo J., Grant T. D., Murphy B. J., Kramer R. H., and Sutherland R. M.. 1994. Selective down-regulation of integrin receptors in spheroids of squamous cell carcinoma. Cancer Res. 54:838–843.
   PubMedGoogle Scholar
• Wartenberg, M., Fischer K., Hescheler J., and Sauer H.. 2000. Redox regulation of P-glycoprotein-mediated multidrug resistance in multicellular prostate tumor spheroids. Int. J. Cancer 85:267–274.
   PubMedGoogle Scholar
• Wood, R. D., Mitchell M., Sgouros J., and Lindahl T.. 2001. Human DNA repair genes. Science 291:1284–1289.
   PubMed Web of Science ®Google Scholar